Pneumococcal conjugate vaccination: Correlates of protection

The Lancet Infectious Diseases

Volumn 14, Issue 9, 2014, Pages 784-786

  Vila Corcoles, Angel ^a   Ochoa Gondar, Olga ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY TITER; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; NOTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

HUMANS; PNEUMOCOCCAL VACCINES;

EID: 84906794266     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70849-7     Document Type: Note

References (11)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. for the Hib and Pneumococcal Global Burden of Disease Study Team.
2. Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014, published online July 18. http://dx.doi.org/10.1016/S1473-3099(14)70822-9.
3. Hausdorff WP, Feikin DR, Klugman KP Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5:83-93.
4. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
5. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
6. Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series 927 2005, WHO, World Health Organization, Geneva.
7. Prymula R, Schuerman L 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8:1479-1500.
8. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17:1017-1026.
9. Nunes MC, Madhi SA Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines 2011, 10:951-980.
10. Miller E, Andrews NJ, Waight PA, Slack MP, George RC Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
11. Weinberger DM, Malley R, Lipsitch M Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.